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AbstrAct 
background Little is known about the prevalence of 
severe, uncontrolled eosinophilic asthma (SUEA) and 
associated costs.
Aims We sought to determine the prevalence of SUEA 
and compare asthma-related healthcare resource use 
(HCRU) and associated costs with overall means for a 
general asthma population.
Methods This cohort study evaluated anonymised 
medical record data (December 1989 through June 
2015) from the Clinical Practice Research Datalink and 
the Optimum Patient Care Research Database to study 
UK patients with active asthma (diagnostic code and one 
or more drug prescriptions in the baseline year), aged 5 
years and older, without concomitant COPD, and with 
recorded eosinophil count. SUEA was defined as two or 
more asthma attacks during 1 baseline year preceding 
a high blood eosinophil count (≥0.3×109/L) for patients 
prescribed long-acting β2-agonist (LABA) and high-
dosage inhaled corticosteroids (ICS) during baseline plus 
1 follow-up year. We compared asthma-related HCRU 
and associated direct costs (2015 pounds sterling, £) 
during the follow-up year for SUEA versus the general 
asthma population.
results Of 363 558 patients with active asthma and 
recorded eosinophil count, 64% were women, mean (SD) 
age was 49 (21) years; 43% had high eosinophil counts, 
7% had two or more attacks in the baseline year and 
10% were prescribed high-dosage ICS/LABA for 2 study 
years. Overall, 2940 (0.81%; 95% CI 0.78% to 0.84%) 
patients had SUEA. Total mean per-patient HCRU and 
associated costs were four times greater for SUEA versus 
all patients (HCRU and cost ratios 3.9; 95% CI 3.7 to 
4.1).
conclusions Less than 1% of patients in a general 
asthma population had SUEA. These patients accounted 
for substantially greater asthma-related HCRU and costs 
than average patients with asthma.
IntroductIon
Asthma currently affects an estimated 358 million 
individuals worldwide, posing a substantial burden 
on healthcare systems.1 While most asthma can be 
controlled with available therapies, some patients 
experience symptoms and severe asthma attacks 
even with high-intensity therapy (ie, Global Initia-
tive for Asthma (GINA) Step 4/5 therapy with 
high-dosage inhaled corticosteroids (ICS) plus 
another controller medication and/or systemic 
corticosteroids2). These patients with severe uncon-
trolled asthma comprised 2.3%–3.6% of patients 
with persistent asthma in recent population-based 
studies using administrative and prescribing data-
bases.3 4 Uncontrolled asthma accounts for a 
disproportionate share of asthma-related healthcare 
resource use (HCRU) and costs.5 6
Eosinophilic asthma is a common phenotype of 
severe asthma,7–10 and patients with eosinophilic 
asthma are at heightened risk of asthma attacks.11–15 
Biological agents mepolizumab and reslizumab 
that target the interleukin-5 molecule directly to 
reduce eosinophils have been demonstrated to 
reduce asthma attacks and improve symptoms in 
patients with severe, uncontrolled eosinophilic 
asthma (SUEA), with the potential to reduce patient 
exposure to high dosages of ICS and oral corti-
costeroids (OCS) and related adverse effects.16–19 
Benralizumab targets the interleukin-5 receptor 
α and induces direct, rapid and nearly complete 
depletion of eosinophils. In the phase III SIROCCO 
and CALIMA trials, benralizumab significantly 
reduced exacerbations, increased lung function 
and improved asthma symptoms for patients with 
severe, uncontrolled asthma with eosinophilic 
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Key messages
What is the key question?
 ► How prevalent is severe, uncontrolled 
eosinophilic asthma, and what are the 
associated healthcare resource use and 
costs as compared with the average asthma 
population?
What is the bottom line?
 ► Severe, uncontrolled eosinophilic asthma is 
uncommon but is associated with asthma-
related healthcare resource use and costs that 
are four times greater than those for average 
patients with asthma.
Why read on?
 ► This study quantifies and contrasts the asthma-
related burden, healthcare resource use, and 
costs during 2 years of observation for patients 
with severe, uncontrolled eosinophilic asthma 
compared with a general asthma population in 
the UK.
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Asthma
inflammation.20 21 While benralizumab is effective across the full 
spectrum of patients studied,20 the best responses to these agents 
are associated with greater eosinophil counts and asthma attack 
rates.16 20 Therefore, information is needed on the prevalence of 
SUEA and associated HCRU to understand the patient popula-
tion for which the use of these medications is justified.
Administrative and electronic databases afford the oppor-
tunity to study large numbers of patients.22 In the UK, anony-
mised databases are available that draw on centralised electronic 
medical records housed at primary care practices. The aims of 
this historical follow-up study were to determine the population 
burden of SUEA and to estimate the asthma-related HCRU and 
associated costs. Our first objective was to describe the distri-
bution of asthma severity and control, treatment status, high 
blood eosinophil count and their combinations and to establish 
the proportion of patients with SUEA in the general UK general 
population. Our second objective was to determine the asth-
ma-related HCRU and associated costs for SUEA as compared 
with those for a general asthma population.
Methods
data source
This historical follow-up study was performed using datasets 
extracted from the Clinical Practice Research Datalink (CPRD) 
and the Optimum Patient Care Research Database (OPCRD), 
which contain anonymised, longitudinal medical record data 
from >650 and 500 UK primary care practices, respectively, 
for patients from throughout the UK. The data include infor-
mation from general practice (GP) visits as well as secondary 
care and hospital attendances. The CPRD, formerly known as 
the General Practice Research Database (GPRD), is a well-main-
tained and well-regarded database that has been used for public 
health research since 1987.23 24 The OPCRD is a bespoke data-
base designed for use in clinical and epidemiological research.25
Two datasets were constructed separately using CPRD and 
OPCRD data in a patient unidentifiable form with harmonised 
variables. The datasets were checked for overlapping data to 
exclude any duplicate data (details in online supplementary mate-
rial). The CPRD dataset contained patient records from June 
1994 through January 2015 and was linked for a percentage of 
patients to Hospital Episode Statistics (HES), a data warehouse 
containing more complete and reliable information on inpatient 
hospital admissions.26 The OPCRD dataset contained patient 
records from December 1989 through June 2015.
The study was performed in compliance with all applicable 
local and national laws and regulations, including approvals for 
dataset use and the study protocol, and in accordance with stan-
dards suggested for observational studies (see online supplemen-
tary material).27
study design and patients
Patients eligible for inclusion in this study were ≥5 years old at 
the time of their most recent asthma diagnoses, recorded as a 
diagnostic Read code for asthma qualifying for inclusion in the 
register of patients with asthma, which general practices in the 
UK maintain for the Quality Outcomes Framework (QOF).28 In 
addition, eligible patients had at least one valid blood eosino-
phil count after their asthma diagnoses and ≥2 years of contin-
uous data used for this study, including ≥1 year (baseline year 
for patient characterisation) before their last recorded eosino-
phil count, and ≥1 year after the eosinophil count (outcome 
year). The date of the last recorded blood eosinophil count 
was defined as the index date, and eligible patients had to have 
received at least one prescription for asthma during the base-
line year. Patients with asthma and no concomitant diagnosis 
of chronic obstructive pulmonary disease (COPD) constituted 
the main study population; and patients ≥40years with both 
asthma and COPD diagnoses were assessed in separate anal-
yses. Patients with a diagnostic Read code for chronic lower 
respiratory conditions other than asthma or COPD, such as 
bronchiolitis obliterans or cystic fibrosis, were excluded from 
the study.
study measures and definitions
We defined severe asthma as combination maintenance therapy 
with high-dosage ICS and long-acting β2-agonist (LABA) in 
both the baseline and the outcome years29; uncontrolled asthma 
as two or more asthma attacks in the baseline year30; and eosin-
ophilic asthma as a blood eosinophil count of ≥0.3×109/L at 
index date.9 10 31 We defined patients as having SUEA if they 
were receiving high-dosage ICS plus LABA in both baseline and 
outcome years, had two or more attacks in the baseline year 
and had a high blood eosinophil count of ≥0.3×109/L at index 
date.
The three components of the composite definition of SUEA 
were based on several sources. The definition of severe asthma 
was based on the definition of high-dosage ICS in the 2014 British 
guideline on the management of asthma, namely as a cumula-
tive chlorofluorocarbon beclomethasone dipropionate (BDP)–
equivalent dosage of ≥800 µg/day for adults and ≥400 µg/day 
for children 5‒12 years.29 We calculated the ICS daily dosage 
separately for the baseline and outcome years using the cumu-
lative ICS exposure based on all prescriptions for each year (see 
online supplementary material). Asthma attacks were defined, 
according to the consensus European Respiratory Society/Amer-
ican Thoracic Society task force definition of severe asthma 
exacerbations, as the occurrence of any of the following events: 
respiratory-related hospital attendance or admission, emergency 
department (ED) attendance or acute OCS course.30 A blood 
eosinophil count of ≥0.3×109/L was chosen as reported to be 
optimal for predicting sputum eosinophilia of ≥3%, reflecting 
airway eosinophilia.9 10 31
Risk-domain asthma control was defined as the absence of 
asthma attacks and no antibiotic prescribed with evidence of 
a lower respiratory consultation. Overall asthma control was 
defined as attainment of risk-domain asthma control plus a mean 
daily dosage of ≤200 µg salbutamol (or ≤500 µg terbutaline).
We determined asthma treatment step according to the GINA 
guidelines using the highest step during the baseline year, with 
the daily dosage of ICS based on the last prescription before the 
index date (see online supplementary material).29
We assessed asthma-related HCRU, including medications, 
asthma-related GP and hospital-based specialist clinic visits, 
hospitalisations and lower respiratory-related ED visits during 
the outcome year. With regard to HCRU that occurred on the 
index date, we assessed HCRU events (eg, GP visits or hospi-
talisations) as being part of the baseline year, because exacer-
bations, for example, might have been a reason for doing a full 
blood count (including eosinophil count), which defined the 
index date. Instead, medications prescribed on the index date 
were included in the outcome year tallies as treatment during 
the outcome period. Asthma-related direct costs during the 
outcome year were determined using standard unit costs for the 
UK National Health Service for 2015 (see online supplementary 
material).
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Figure 1 Patient flow chart. *Active asthma was defined as one or 
more prescriptions for asthma medication in the baseline year and 
asthma not resolved. †Includes those aged ≥40 years with concomitant 
COPD diagnosis. COPD, chronic obstructive pulmonary disease; CPRD, 




We used summary statistics to describe the distribution of asthma 
severity and control, treatment status, high blood eosinophil 
counts, other asthma determinants and their combinations in the 
baseline year before the index date, and we described mean asth-
ma-related HCRU and associated direct costs during the outcome 
year. Although the distributions were skewed, we reported the 
means for HCRU, costs and cost ratios as recommended.32–34 
The means can be multiplied by a target population to estimate 
total costs and are therefore of most use to policy-makers and 
providers.
We performed the analyses separately for patients with and 
without a concomitant diagnosis of COPD. Analyses for those 
with concomitant COPD included only patients aged ≥40 years, 
described in the online supplementary material.
The mean numbers of HCRU events per patient during the 
outcome year were calculated with SDs. The means were then 
multiplied by unit costs for the cost year 2015 (expressed as 
pounds sterling, £) to provide mean (SD) annual, asthma-related 
healthcare costs for individuals (details in online supplementary 
material). The HCRU and cost analyses requiring information 
about inpatient hospitalisations were performed for the subgroup 
of patients in the CPRD dataset who had linked HES data. Sensi-
tivity analyses on HCRU and costs were performed using different 
definitions of SUEA based on three additional definitions of 
high eosinophil count, namely ≥0.2×109/L, ≥0.4×109/L 
and ≥0.5×109/L. The HCRU and costs were described also for 
patients with prescriptions for maintenance oral corticosteroids. 
Cost ratios were estimated by calculating the ratios of the mean 
costs for the subgroup of patients with SUEA to those for the 
reference group of all patients with asthma. All 95% CIs were 
estimated based on 1000 bootstrap replicates (see online supple-
mentary material).
Analyses were performed using IBM SPSS Statistics V.23 (IBM 
SPSS Statistics, Feltham, Middlesex, UK) and R V.3.0.2 (The R 
Project for Statistical Computing; https://www. r- project. org/).
results
Patient populations
In the two databases, 1 016 696 of 2 117 427 patients (48%) 
with asthma diagnostic code had recorded eosinophil counts. 
Of these, we identified a total of 401 261 (39%) patients with 
active asthma who met all eligibility criteria (figure 1). The main 
study population (those without a concomitant COPD diag-
nosis) included 363 558 (91%) patients with active asthma who 
had index dates from 6 December 1990 to 23 June 2014, with 
a median (IQR) index date year of 2011 (2008–2012); 0.7% of 
patients had an index date before the year 2000. Our findings 
for the 37 703 (9%) patients ≥40 years old with concomitant 
diagnosis of COPD are reported in the online supplementary 
material.
demographic and clinical characteristics and asthma burden
In the main study population, 24 047 (7%) patients experienced 
two or more attacks during the baseline year; 34 898 (10%) 
received high-dosage ICS plus LABA during both baseline and 
outcome years; and 6326 (1.7%) received high-dosage ICS plus 
LABA during both baseline and outcome years and also experi-
enced two or more attacks during the baseline year. Of the 6326 
patients, a total of 2940 patients (46.5%), or 0.81% (95% CI 
0.78% to 0.84%) of the main study population, met the study 
definition of SUEA, namely high-dosage ICS plus LABA in both 
baseline and outcome years, two or more attacks in the baseline 
year and high blood eosinophil count of ≥0.3×109/L at the 
index date.
Tables 1 and 2 summarise demographics and baseline clinical 
characteristics for all ages combined (≥5 years) and for adults 
(18–64 and ≥65 years) in the SUEA population and the main 
study population. The median (IQR) index date years were 2011 
(2009–2013) for SUEA and 2011 (2008–2012) for the total 
population. Most patients with SUEA were ≥18 years. Only 57 
patients (2%) were <18 years, including 14 children who were 
5–11 years old and 43 who were 12–17 years old (online supple-
mentary table S1). Overall, the SUEA population was older 
than the main study population—983 (33%) and 95 189 (26%) 
were ≥65 years, respectively—but included roughly the same 
proportion of female patients (1952 (66%) and 233 210 (64%) 
female, respectively) (table 1). On the index date, blood eosin-
ophil counts of ≥0.3×109/L were recorded for 156 136 (43%) 
patients, including 91 865/233 210 (39%) female patients and 
64 271/130 348 (49%) male patients (table 2).
The 2940 patients in the SUEA population and those in each 
of the adult SUEA cohorts, compared with patients in the main 
study population, were less likely to have been normal weight, 
more likely to have been obese, and more likely to have had 
recorded comorbidities, with the greatest differences between 
SUEA and main populations overall in the recorded frequency 
of nasal polyps, followed by non-allergic rhinitis, chronic 
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table 1 Demographics and baseline clinical characteristics of the main study population (including patients with SUEA) and the SUEA population: 
all ages (≥5 years) and the adult cohorts














Female sex, n (%) 233 210 (64.1) 1952 (66.4) 158 507 (65.3) 1269 (66.8) 61 990 (65.1) 650 (66.1)
Age at index date, mean (SD) 49.4 (20.6) 55.8 (17.6) 43.0 (12.8) 47.1 (11.6) 75.5 (7.5) 74.9 (7.1)
Body mass index, n (%)†
  Underweight 10 152 (3.3) 47 (1.8) 3948 (1.9) 18 (1.0) 1642 (1.9) 20 (2.2)
  Normal 96 309 (31.0) 674 (25.1) 64 852 (30.7) 406 (23.4) 24 984 (29.0) 254 (27.6)
  Overweight 100 937 (32.4) 828 (30.8) 67 176 (31.8) 489 (28.2) 32 116 (37.3) 333 (36.2)
  Obese 103 738 (33.3) 1135 (42.3) 75 319 (35.6) 821 (47.3) 27 470 (31.9) 312 (33.9)
  Unknown, n 52 422 256 31 419 166 8977 64
Smoking status, n (%)†
  Current smoker 64 350 (18.0) 530 (18.3) 56 194 (23.4) 476 (25.3) 6218 (6.6) 45 (4.6)
  Ex-smoker 93 359 (26.2) 899 (31.0) 56 807 (23.7) 523 (27.8) 35 941 (38.2) 376 (38.6)
  Never smokers 199 299 (55.8) 1475 (50.8) 126 664 (52.9) 879 (46.8) 51 906 (55.2) 554 (56.8)
  Unknown, n 6550 36 3049 22 1124 8
Charlson comorbidity index, n (%)
  0 166 280 (45.7) 669 (22.8) 118 122 (48.7) 424 (22.3) 35 111 (36.9) 232 (23.6)
  1–4 170 791 (47.0) 1941 (66.0) 114 735 (47.3) 1337 (70.4) 43 500 (45.7) 560 (57.0)
  ≥5 26 487 (7.3) 330 (11.2) 9857 (4.1) 139 (7.3) 16 578 (17.4) 191 (19.4)
Ever-recorded comorbidity, n (%)
  Eczema 105 659 (29.1) 999 (34.0) 68 507 (28.2) 661 (34.8) 25 188 (26.5) 302 (30.7)
  Allergic rhinitis 62 490 (17.2) 608 (20.7) 45 790 (18.9) 427 (22.5) 12 789 (13.4) 163 (16.6)
  Non-allergic rhinitis 32 285 (8.9) 422 (14.4) 19 918 (8.2) 245 (12.9) 10 825 (11.4) 172 (17.5)
  Chronic sinusitis 35 708 (9.8) 456 (15.5) 24 940 (10.3) 287 (15.1) 10 351 (10.9) 169 (17.2)
  Nasal polyps 12 949 (3.6) 376 (12.8) 7070 (2.9) 218 (11.5) 5802 (6.1) 158 (16.1)
  Gastro-oesophageal reflux disease 42 154 (11.6) 515 (17.5) 25 129 (10.4) 293 (15.4) 16 323 (17.1) 221 (22.5)
  Cardiovascular disease 93 443 (25.7) 1080 (36.7) 44 393 (18.3) 507 (26.7) 48 411 (50.9) 572 (58.2)
*All patients with SUEA included 14 children who were 5–11 years old and 43 adolescent patients 12–17 years old.
†The percentages for BMI and for smoking status were calculated for patients with available data. Overall, patients with missing data for BMI represented 14% of patients 
and for smoking status, 2% of patients. The BMI categories, determined from data closest to the index date, were defined as follows: underweight, <18.5 kg/m2; normal 
weight, ≥18.5 kg/m2 to <25 kg/m2); overweight, ≥25 kg/m2 to <30 kg/m2; and obese, ≥30 kg/m2 for patients ≥18 years old. (For children BMI was not calculated because accurate 
information on age in months required to calculate BMI z-scores was not provided for privacy reasons.)
BMI, body mass index; SUEA, severe, uncontrolled eosinophilic asthma.
Asthma
sinusitis, gastro-oesophageal reflux disease, cardiovascular 
disease and evidence of atopy (eczema and allergic rhinitis; see 
table 1).
Patients with SUEA also had lower mean percent predicted 
peak expiratory flow rate (67% vs 77%) and, on average, a much 
greater asthma medication burden than did patients in the main 
study population (table 2). Almost all patients with SUEA (2881 
(98%)]) were at GINA step 4 or 5 based on the ICS prescrip-
tion preceding the index date, while approximately one-third 
of patients (113 543 (31%)) in the main population were at 
step 4 or 5. The median (IQR) ICS dosage exposures during the 
baseline year in SUEA and main populations were 1425 (1068–
1967 µg/day) and 329 µg/day (132–658 µg/day), respectively; 
and maintenance OCS were prescribed for 488 (17%) and 10 
522 (3%) patients, respectively.
Demographics and baseline clinical characteristics of patients 
with SUEA defined using different definitions of high blood 
eosinophil count are described in online supplementary table 
S2. The prevalence of SUEA ranged from 1.2% at an eosinophil 
count of ≥0.2×109/L to 0.3% at a count of ≥0.5×109/L.
healthcare resource use and costs
The mean HCRU and direct, asthma-related costs for each 
HCRU-related category were from 2.5 to 7.6 times greater for 
the SUEA cohort than for the main study population with active 
asthma, as summarised in table 3. The mean number of GP visits 
was 2.7 for the SUEA cohort and 1.4 for the main population, 
and the mean numbers of hospital-based specialist visits were 
0.30 versus 0.04, respectively. During the outcome year, 627 of 
the 2940 patients in the SUEA cohort (21.3%) experienced two 
asthma attacks, and 387 (13.2%) and 393 (13.4%) experienced 
three and four or more attacks, respectively. Corresponding 
numbers for the main population of 363 558 patients with active 
asthma were 13 556 (3.7%), 5165 (1.4%) and 2987 (0.8%), 
respectively (online supplementary table S3).
The total mean asthma-related costs were £861 for the SUEA 
cohort versus £222 for the main study population, for a cost 
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table 2 Clinical characteristics and asthma disease burden of the main study population (including patients with SUEA) and the SUEA population: 
all ages (≥5 years) and the adult cohorts














Blood eosinophil count, median (IQR) 0.20 (0.11–0.35) 0.40 (0.30–0.60) 0.20 (0.12–0.34) 0.40 (0.30–0.60) 0.20 (0.10–0.30) 0.40 (0.30–0.55)
Blood eosinophil count ≥0.3×109/L, n (%) 156 136 (42.9) 2940 (100) 103 298 (42.6) 1900 (100) 37 629 (39.5) 983 (100)
  Female patients, n (% of females) 91 865 (39.4) 1952 (100) 63 086 (39.8) 1269 (100) 22 010 (35.5) 650 (100)
  Male patients, n (% of males) 64 271 (49.3) 988 (100) 40 212 (47.8) 631 (100) 15 619 (47.0) 333 (100)
% Predicted PEF
  Available data, n (%) 277 334 (76.3) 2614 (88.9) 199 539 (82.2) 1762 (92.7) 77 795 (81.7) 852 (86.7)
  Mean (SD) 77.4 (17.4) 66.6 (18.6) 79.2 (16.7) 67.2 (18.5) 72.8 (18.4) 65.3 (18.8)
Mean daily SABA dosage (µg/day), n (%)†
  0 74 637 (20.5) 610 (20.7) 46 517 (19.2) 354 (18.6) 25 475 (26.8) 250 (25.4)
  1–200 148 727 (40.9) 315 (10.7) 102 914 (42.4) 180 (9.5) 31 601 (33.2) 132 (13.4)
  201–400 72 073 (19.8) 504 (17.1) 47 377 (19.5) 286 (15.1) 19 035 (20.0) 211 (21.5)
  >400 68 121 (18.7) 1511 (51.4) 45 906 (18.9) 1080 (56.8) 19 078 (20.0) 390 (39.7)
Asthma therapy: GINA step, n (%)‡
  Step 1 58 159 (16.0) 0 43 676 (18.0) 0 8723 (9.2) 0
  Step 2 115 346 (31.7) 0 77 732 (32.0) 0 26 297 (27.6) 0
  Step 3 76 510 (21.0) 59 (2.0) 49 070 (20.2) 40 (2.1) 21 874 (23.0) 17 (1.7)
  Step 4 103 019 (28.3) 2393 (81.4) 67 661 (27.9) 1547 (81.4) 32 511 (34.2) 798 (81.2)
  Step 5 10 524 (2.9) 488 (16.6) 4575 (1.9) 313 (16.5) 5784 (6.1) 168 (17.1)
Prescribed ICS during the baseline year, n 
(%)
300 920 (82.8) 2940 (100) 196 640 (81.0) 1900 (100) 84 615 (88.9) 983 (100)








Last ICS dosage prescribed, per GINA 
classification, n (%)‡
  No ICS prescribed 62 638 (17.2) 0 46 074 (19.0) 0 10 574 (11.1) 0
  Low ICS dosage 159 858 (44.0) 114 (3.9) 105 503 (43.5) 75 (3.9) 39 438 (41.4) 35 (3.6)
  Medium ICS dosage 107 207 (29.5) 943 (32.1) 69 839 (28.8) 569 (29.9) 33 094 (34.8) 330 (33.6)
  High ICS dosage 33 855 (9.3) 1883 (64.0) 21 298 (8.8) 1256 (66.1) 12 083 (12.7) 618 (62.9)
≥1 prescription during baseline, n (%)
  Omalizumab 3 (0) 0 (0) 3 (0) 0 0 0
  LTRA 21 436 (5.9) 1001 (34.0) 14 209 (5.9) 743 (39.1) 5092 (5.3) 216 (22.0)
  Theophylline 6073 (1.7) 397 (13.5) 3333 (1.4) 276 (14.5) 2676 (2.8) 116 (11.8)
Cumulative high-dosage ICS, n (%)† 59 953 (16.5) 2940 (100) 34 463 (14.2) 1900 (100) 24 327 (25.6) 983 (100)
Cumulative high-dosage ICS+LABA, n (%)† 46 687 (12.8) 2940 (100) 27 526 (11.3) 1900 (100) 18 419 (19.3) 983 (100)
Cumulative high-dosage ICS+LABA 
for 2 years, n (%)†§
34 898 (9.6) 2940 (100) 20 336 (8.4) 1900 (100) 14 128 (14.8) 983 (100)
Maintenance OCS, n (%)¶ 10 522 (2.9) 488 (16.6) 4573 (1.9) 313 (16.5) 5784 (6.1) 168 (17.1)
Asthma attacks, mean (SD) 0.31 (0.76) 2.89 (1.32) 0.30 (0.74) 2.93 (1.35) 0.36 (0.84) 2.80 (1.27)
  Median (range) 0 (0–15) 2 (2–14) 0 (0–15) 3 (2–14) 0 (0–14) 2 (2–13)
  0 attacks, n (%) 288 836 (79.4) 0 193 674 (79.8) 0 73 362 (77.1) 0
  1 attack, n (%) 50 675 (13.9) 0 33 621 (13.9) 0 14 229 (14.9) 0
  2–3 attacks, n (%)** 20 793 (5.7) 2307 (78.5) 13 415 (5.5) 1464 (77.1) 6434 (6.8) 800 (81.4)
  ≥4 attacks, n (%)** 3254 (0.9) 633 (21.5) 2004 (0.8) 436 (22.9) 1164 (1.2) 183 (18.6)
Risk-domain asthma control, n (%) 232 944 (64.1) 244 (8.3) 157 232 (64.8) 151 (7.9) 58 070 (61.0) 90 (9.2)
Overall asthma control, n (%) 149 349 (41.1) 77 (2.6) 100 694 (41.5) 43 (2.3) 36 490 (38.3) 33 (3.4)
Cumulative high-dosage ICS+LABA and 
≥2 attacks, n (%)
8164 (2.2) 2940 (100) 5098 (2.1) 1900 (100) 2919 (3.1) 983 (100)
Continued
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Cumulative high-dosage ICS+LABA and 
≥4 attacks, n (%)
1569 (0.4) 633 (21.5) 1011 (0.4) 436 (22.9) 533 (0.6) 183 (18.6)
*All patients with SUEA included 14 children who were 5–11 years old and 43 adolescent patients 12–17 years old.
†SABA and cumulative ICS dosage exposure during the baseline year were calculated as the mean of recorded prescriptions over 365 days. High-dosage ICS was defined, using 
chlorofluorocarbon beclomethasone dipropionate-equivalent dose, according to 2014 British asthma guidelines as a cumulative beclomethasone-equivalent dosage of ≥800 µg/
day for adults and ≥400 µg/day for children 5‒12 years.29
‡GINA treatment steps were defined using the last prescribed ICS dosage before the index date and applying low-dosage, medium-dosage and high-dosage ICS definitions per 
GINA guidelines (details in the online supplementary material).2
§Study definition of severe asthma, that is, cumulative high-dosage ICS+LABA during both baseline and outcome years.
¶Maintenance OCS at some time during the baseline year.
**The study definition of uncontrolled asthma was 2 or more attacks during the baseline year.
GINA, Global Initiative for Asthma; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting β2-agonist; LTRA, leukotriene receptor antagonist; OCS, oral 
corticosteroids; PEF, peak expiratory flow; SABS, short-acting β2-agonist; SUEA, severe, uncontrolled eosinophilic asthma.
table 2 Continued 
table 3 Mean asthma-related HCRU, associated direct costs (2015 pounds sterling, £), and HCRU and cost ratios during the outcome year for 
patients with SUEA and those receiving maintenance oral corticosteroids compared with all patients with active asthma (including patients with 
SUEA) in the UK general population
All patients
(n=3 63 558/146 485*)
sueA
(n=2940/1206*) hcru and cost ratios
≥1 ocs maintenance
(n=10 522/4140*) hcru and cost ratios
Asthma-related hcru outcome (95% cI)† (95% cI)†
GP visit‡
  Number 1.36 (1.57) 2.67 (2.80) 2.5 (2.4 to 2.6) 1.93 (2.43) 1.7 (1.7 to 1.8)
  Costs £30.8 (49.8) £77.0 (107.5) £53.2 (90.8)
  Costs, median (IQR) £14.5 (0.0–43.4) £44.0 (14.5–101.7) – £28.9 (14.5–58.5) –
Hospital-based specialist visit
  Number 0.04 (0.33) 0.30 (0.96) 6.8 (6.0 to 7.7) 0.31 (0.96) 5.7 (5.3 to 6.2)
  Costs £6.9 (52.2) £46.7 (149.2) £39.4 (138.6)
Asthma-related ED attendance
  Number 0.01 (0.11) 0.04 (0.25) 4.1 (3.2 to 5.3) 0.03 (0.23) 3.4 (3.0 to 4.0)
  Costs £1.6 (18.8) £6.6 (44.7) £5.5 (38.2)
Hospitalisation*
  Number 0.01 (0.12) 0.05 (0.38) 7.6 (4.7 to 11.6) 0.04 (0.37) 6.7 (5.0 to 8.9)
  Costs £10.4 (194.7) £78.7 (660.3) £69.6 (653.5)
Medication cost £170.1 (218.2) £645.4 (285.4) 3.8 (3.7 to 3.9) £363.6 (338.6) 2.1 (2.1 to 2.2)
  Cost, median (IQR) £87.8 (18.0–244.9) £595.3 (451.8–760.5) – £285.2 (111.4–527.0) –
Total costs* £222.0 (337.2) £861.0 (811.9) 3.9 (3.7 to 4.1) £552.1 (842.8) 2.5 (2.4 to 2.6)
  Total costs, median (IQR) £125.6 (43.1–297.9) £707.0 (523.0–951.0) – £370.0 (159.6–689.7) –
Data are reported as mean (SD) unless otherwise noted. The medians (IQRs) that are not included in the table were all 0 (0–0).
*The second number of patients in the column headers represents those in the Clinical Practice Research Datalink who had linked Hospital Episode Statistics (HES), used to 
determine hospitalisations and associated costs, as factored into total costs. The SUEA cohort with HES data included 26 (2.2%) patients <18 years old.
†95% CI, based on 1000 bootstrap replicates.
‡GP visits included consultations with primary care physicians and asthma nurses.
ED, emergency department; GP, general practice; HCRU, healthcare resource use; OCS, oral corticosteroids; SUEA, severe, uncontrolled eosinophilic asthma.
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ratio of 3.9 (95% CI 3.7 to 4.1). The asthma-related HCRU 
and associated cost ratios for patients with SUEA appeared to 
increase with the increasing blood eosinophil counts used to 
define SUEA, ranging from 3.8 (95% CI 3.7 to 4.0) for an eosin-
ophil count of ≥0.2×109/L to 4.2 (95% CI 3.8 to 4.7) for a 
count of ≥0.5×109/L (online supplementary table S4).
For the 10 552 patients in the main study population who 
received maintenance OCS during the baseline year, the total 
mean costs, including medication costs, were £552, for a cost 
ratio of 2.5 (95% CI 2.4 to 2.6) relative to all patients with 
asthma (table 3).
Patients ≥40 years old with concomitant coPd
Demographics and baseline clinical characteristics of patients ≥40 
years with asthma and concomitant COPD are described in 
the online supplementary table S5. The percentage of these 
patients who had SUEA (blood eosinophil count ≥0.3×109/L) 
was greater than in the main study population (1596/37 703 or 
4.2% vs 0.8% (2940/363 558) in the main population) (online 
supplementary table S1).
The mean asthma-related HCRU and costs for the total popula-
tion of patients with concomitant COPD were much higher than 
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those for the main study population with asthma but without 
concomitant COPD (total mean costs of £530 vs £222, respec-
tively). Patients with SUEA and concomitant COPD had total 
mean costs of £866. Thus, the cost ratio for patients ≥40 years 
old with SUEA and concomitant COPD versus patients ≥40 
years with asthma and concomitant COPD was 1.6 (95% CI 1.6 
to 1.7) (online supplementary table S6).
dIscussIon
We identified a total of 2940 patients, representing <1% of 
patients in a general UK asthma population without concomitant 
COPD, as having SUEA, which we defined as at least two asthma 
attacks in the year before a recorded high blood eosinophil count 
(≥0.3×109/L) while receiving treatment with high-dosage ICS 
plus LABA during the 2 consecutive years bracketing the eosin-
ophil count. Sixty-six percent of the patients with SUEA were 
women. They were older on average (56 vs 49 years old), and 
they had more frequent comorbidities than other patients with 
asthma. Moreover, the individuals with SUEA had greater asth-
ma-related disease burden, consulting their general practitioners 
for asthma twice as frequently, and visiting the hospital-based 
specialist clinics seven times as frequently as the general asthma 
population. During the outcome year after the eosinophil count, 
they presented substantially greater asthma-related HCRU and 
associated direct costs, four times greater than those for the main 
study population of patients with active asthma.
Costs for HCRU in the UK are relatively lower than in some 
other countries. Therefore, the absolute difference in total costs 
between patients with SUEA and all patients with asthma may 
be greater in countries with more expensive healthcare systems, 
such as the USA.35 In a recent US study, the total mean, annual 
asthma-related costs for 101 patients with severe, uncontrolled 
asthma and eosinophil count of ≥0.3×109/L were US$3030 
(2013 US dollars), roughly four times greater than the analo-
gous costs in our study.36 We found that asthma medications 
comprised approximately 75% of total mean costs incurred by 
patients in each of the SUEA and general asthma populations 
and, thus, were the largest category of asthma-related costs in 
this study, similar to findings in other studies of severe uncon-
trolled asthma in the USA and UK.4 5 36 A 2009 systematic review 
of 68 studies evaluating the economic burden of asthma identi-
fied medications or hospitalisations, depending on the study, as 
being the major drivers of asthma-related direct costs.6
We found greater asthma-related disease burden also in the 
subgroup of patients with concomitant COPD and elevated 
blood eosinophils, as reported by others.37 The total mean asth-
ma-related costs were similar for the two SUEA populations 
(those with and without concomitant COPD, £865 and £861, 
respectively). However, the cost ratio for those with SUEA and 
concomitant COPD was just 1.6 because of greater total mean 
costs (£530) for all patients with concomitant COPD, likely 
because they were older (all ≥40 years) and had more frequent 
comorbidities. Others have found that asthma-related healthcare 
costs for patients with asthma and concomitant COPD are nearly 
double those for matched patients with asthma without COPD.38 
The subgroup of patients on maintenance OCS had mean total 
costs 2.5 times greater than those for the main study population.
Strengths of this study include the large general asthma popu-
lation (>350 000 patients with active asthma) and the use of 
well-maintained databases of electronic medical records that 
are used frequently for observational research. We examined 
1 baseline year, a standard interval used to clinically charac-
terise patients, followed by 1 full outcome year to account 
for seasonal variation in asthma symptoms and considered a 
minimum interval for follow-up, as used in prior observational 
studies.11–13 35–39 Over 99% of patients in both main and SUEA 
populations had index dates after 1999, the year when the first 
fixed-dose combination ICS/LABA was introduced in the UK. 
Moreover, 91% of the main study population (and 94% of the 
SUEA population) had index dates in 2005 or later; therefore, 
most of the data were post-2004 and thus after the introduction 
on 1 April 2004 of the UK Quality Outcomes Framework (QOF) 
establishing incentives for improved data recording at GP prac-
tices.28 Indeed, smoking status, for example, was recorded for all 
but 2% of patients. Nonetheless, information on spirometry was 
limited, especially with regard to bronchodilator reversibility, 
which was available for only approximately 1% of patients. The 
datasets represent information collected for clinical and routine 
use rather than specifically for research purposes. Moreover, 
reports from hospital registrars and referrals to chest physicians, 
in addition to eosinophil counts determined in hospital or the 
ED, may not have been consistently incorporated in patients’ 
general practitioner records. For this reason, we restricted the 
calculation of hospitalisations and associated costs to the subset 
of patients in the CPRD who were also included in the HES 
dataset.
Our choice of ≥0.3×109/L blood eosinophils as the primary 
definition of high blood eosinophil count is in line with prior 
reports that found eosinophil thresholds of 0.27×109/L and 
0.26×109/L to be optimal for predicting sputum eosinophilia 
of ≥3%.9 10 31 Our definition of high-dosage ICS used in the 
SUEA definition was less than that defined as the high dosage in 
ERS/ATS guidelines defining severe asthma (ie, BDP ≥2000 µg/
day for adults and ≥800 µg/day for children).8 However, the 
mean daily ICS dosages during the baseline and outcome years 
were calculated using all prescriptions averaged over 365 days 
(rather than a single prescribed dose) and thus represent total 
ICS exposure during the year.
Working retrospectively from databases limited our ability 
to separate severe treatment-resistant (refractory) asthma 
(ie, asthma that remains uncontrolled despite GINA Step 4/5 
therapy) from difficult-to-control asthma (ie, uncontrolled 
asthma resulting from poor adherence, poor inhalation tech-
nique or treatable comorbidities, for example).8 In addition, our 
definition of asthma control was limited to items recorded in 
the database that reflected asthma control or lack thereof, such 
as acute OCS prescriptions; we were not able to assess asthma 
symptoms.
We included patients with SUEA in the main study popula-
tion without concomitant COPD (as well as in the total popu-
lation with concomitant COPD), because our aim was to report 
costs for a general asthma population, which, by definition, also 
includes patients with SUEA. Therefore, the main study and 
SUEA cohorts were not mutually exclusive, which caused a slight 
underestimation of the difference between cohorts. In post hoc 
calculations, the mean total costs for the main study population 
excluding SUEA were £216.7 (vs £222.0 when including SUEA), 
giving a cost ratio of 4.0, a difference of only 0.1 versus our 
reported ratio of 3.9.
Our general asthma population may not be fully represen-
tative of all patients with active asthma because we included 
only patients who had a recorded eosinophil count, limiting 
the generalisability of our findings. Eosinophil counts are 
usually performed for a reason, for example, for a health-re-
lated reason that may not be related to asthma. Indeed, previous 
studies report that patients with asthma and recorded eosino-
phil count tend to be older, more commonly female, and with 
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greater asthma-related burden than the general asthma popula-
tion.12 13 Finally, there are several other limitations of working 
retrospectively from databases. Because we restricted our anal-
yses to HCRU with a primary code of asthma, it is possible 
that not all asthma-related direct costs were captured. Some 
consultations for conditions occurring as a result of asthma 
treatment, for example, steroid-induced morbidity, or consulta-
tions not primarily related to asthma that involved discussion 
and management of asthma may not have been coded as being 
asthma-related. Moreover, when assigning costs, although most 
annual asthma reviews in the UK are performed by nurses,40 we 
could not be certain whether all asthma reviews were indeed 
done by nurses and all other consultations by primary care physi-
cians. In addition, we could not assess indirect costs, such as lost 
school and work time,6 because these data are not included in 
patients’ medical records.
We note that patients with SUEA had fewer attacks in the 
outcome year compared with the baseline year (48% vs 100% 
with two or more attacks). This difference could be explained 
by regression to the mean.41 Alternatively, for some patients, 
perhaps their asthma was more aggressively or appropriately 
managed during the outcome year, or the natural history of 
severe asthma could include the transition to less severe asthma 
over time.42
In conclusion, we found that 0.8% of patients in a general UK 
asthma population have SUEA, and 4.2% of those with asthma 
and concomitant COPD have SUEA, defined as having two or 
more asthma attacks in the year before a recorded high blood 
eosinophil count (≥0.3×109/L) and while under treatment for 
2 years with high-dosage ICS plus LABA. Individuals who have 
SUEA despite treatment with high dosages of ICS combined with 
LABA therapy account for substantially greater asthma-related 
HCRU and associated direct costs than average patients with 
asthma.
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